The Numbers Behind Pfizer’s Decision

Share:
Facebook Twitter Google+

Pfizer abandoned a potentially blockbuster cholesterol drug after some patients died during clinical trials. The number of deaths wasn’t much bigger than the number of people in a control group who also died. But a closer look shows how small differences can have big impacts in medical trials. Plus, join a discussion.
WSJ.com: The Numbers Guy